Autologous platelet-derived growth factors (APDGF) / Platelet-rich plasma (PRP)
Cigna medical coverage policy regarding the use of autologous platelet-derived growth factors (APDGF), also referred to as platelet-rich plasma (PRP), for multiple conditions and indications. Defines coverage stance, lists specific indications considered experimental/investigational/unproven, provides background, FDA device context, and summarizes literature evidence.
Annual review completed with no clinical policy statement changes.
Policy updated to new template and formatting standards during the 10/15/2023 annual review.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.